Understanding Pheochromocytomas and Paragangliomas
Author Information
Author(s): Carolijn J. M. de Bresser, Ronald R. de Krijger
Primary Institution: University Medical Center Utrecht
Hypothesis
Can genomic and immune profiling improve the prediction of metastatic potential in pheochromocytomas and paragangliomas?
Conclusion
The study highlights the need for a combination of biomarkers to accurately predict the metastatic risk of pheochromocytomas and paragangliomas.
Supporting Evidence
- Pheochromocytomas and paragangliomas are highly hereditary tumors.
- Recent studies suggest that 10-15% of PCCs and up to 50% of abdominal paragangliomas can become metastatic.
- Genomic profiling has identified potential biomarkers that may influence metastatic potential.
Takeaway
Pheochromocytomas and paragangliomas are tumors that can spread, and scientists are trying to find better ways to predict which ones will become dangerous by looking at their genes and immune responses.
Methodology
The review evaluates current guidelines and genomic findings to identify biomarkers for predicting metastatic potential.
Limitations
The study acknowledges the rarity of cases and the need for further validation of proposed biomarkers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website